Servier Just Paid $2.5 Billion to Bet on Kids' Brain Cancer
Servier is dropping $2.5 billion in cash on Day One Biopharmaceuticals, a one-drug biotech focused on pediatric brain tumors. The deal says something fascinating about where precision oncology is heading, and why rare cancers might be pharma's smartest bet.
A French Giant Goes Shopping in San Francisco
Pediatric brain cancer is not exactly the kind of market that gets Wall Street salivating. The patient population is tiny. The clinical trials are brutal to recruit. And the commercial upside? Most pharma execs would rather chase obesity or Alzheimer's, where the addressable market looks like a phone number.
So when Servier, a privately held French pharma company, agreed to pay $2.5 billion in cash for Day One Biopharmaceuticals, a lot of people had the same reaction: why?
The answer tells you something important about where precision oncology is heading.
The Target: A One-Drug Company With a Big Idea
Day One Biopharmaceuticals built its entire identity around a single drug called Ojemda (tovorafenib). It's a once-weekly pill designed to treat pediatric low-grade glioma (pLGG), a type of brain tumor that mostly hits kids. Specifically, it works in patients whose tumors carry certain BRAF gene alterations, which basically act like a stuck "on" switch telling cancer cells to keep growing.
The FDA granted Ojemda accelerated approval for kids six months and older with relapsed or refractory pLGG. Translation: it's already on the market for children whose tumors came back or didn't respond to earlier treatment. The drug pulled in $155 million in net product revenue in 2025, which is solid for a rare disease drug that just launched.
But Day One was still burning cash. The company posted a $107.3 million net loss last year while investing heavily in its confirmatory Phase 3 trial and earlier-stage pipeline programs. It's the classic biotech catch-22: the drug works, the revenue is growing, but profitability feels like it's always one more trial away.
The Price Tag: Generous, But Calculated
Servier is paying $21.50 per share, all cash, no financing contingencies. The company is funding the entire deal from its own balance sheet. That price represents a 68% premium over Day One's closing price on March 5 and an to its one-month volume-weighted average.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
86% premium
For shareholders who stuck around through biotech's brutal 2022-2023 downturn, this is a lifeline wrapped in a bow. Day One went public in 2021 at $16 per share. Over the past year, the stock bounced between $5.64 and $13.20. Servier is essentially buying above the ceiling of the 52-week range and tacking on a generous premium for good measure.
The market clearly believes the deal gets done. After the announcement, shares traded around $21.17, leaving only a thin 33-cent spread to the offer price. That's the kind of gap that screams "this is happening" in merger-arbitrage terms. Day One's board unanimously recommended that shareholders tender their shares, and closing is expected in Q2 2026, pending U.S. antitrust clearance.
Why Servier Wants to Own Pediatric Oncology
Servier isn't some random buyer. The company has been methodically building a rare cancer franchise for years, and this deal slots in perfectly.
The numbers paint a clear picture. Servier's oncology revenue grew 55% year-over-year in its most recent fiscal year, now accounting for roughly a third of the company's total sales. The broader target is ambitious: €4 billion in oncology revenue by 2030, within a group-wide goal of €10 billion. To get there, Servier needs assets, and it needs them fast.
Day One gives Servier several things at once. First, an approved, revenue-generating drug in pediatric brain tumors. Second, a late-stage clinical program (FIREFLY-2) that could convert Ojemda's accelerated approval into full approval as a first-line treatment. That trial has about 400 patients across 140 sites globally, with enrollment expected to wrap up in the first half of 2026. Third, there's a pipeline of earlier-stage programs, including antibody-drug conjugates with data readouts expected in mid-to-late 2026.
Think of it like buying a house that's already renovated (Ojemda on the market), with permits approved for an addition (FIREFLY-2), and blueprints drawn for a guest house (the ADC pipeline). You're paying a premium, but you're buying optionality at every stage.
The Bigger Picture: Rare Cancers Aren't So Niche Anymore
The pediatric oncology therapeutics market was worth $2.71 billion in 2025 and is projected to hit $4.64 billion by 2032, growing at 8% annually. Those aren't blockbuster-drug numbers individually, but they add up. And the competitive dynamics are wildly different from, say, the obesity drug wars.
In rare cancers, you're not slugging it out with five other GLP-1 drugs for market share. You're often the only game in town. The FDA has approved over 20 molecularly targeted therapies for pediatric cancers since 2015, but the need is still enormous. Only about 9,620 children under 14 were diagnosed with cancer in the U.S. in 2024. That small patient population is both the challenge (hard to run big trials) and the moat (nobody else wants to do the hard work either).
Servier's structure gives it a unique advantage here. As a foundation-owned company, there are no quarterly earnings calls, no activist investors demanding share buybacks. That kind of patient capital is perfectly suited for rare disease markets where the payoff horizon stretches years, not quarters.
How This Stacks Up Against the M&A Frenzy
At $2.5 billion, the Servier/Day One deal is meaningful but not massive by 2025-2026 standards. Johnson & Johnson's $14.6 billion grab of Intra-Cellular Therapies dwarfs it. So does Novartis buying Avidity Biosciences for around $12.7 billion, and Sanofi's $9.5 billion acquisition of Blueprint Medicines.
Among European pharma companies buying U.S. biotechs, Servier sits behind Novartis, Sanofi, Genmab, and Novo Nordisk in deal size. But raw dollars don't tell the whole story. Servier is a €6.86 billion revenue company making a $2.5 billion bet; relative to its size, this is a major commitment. It's the equivalent of a mid-market baseball team trading its top three prospects for a proven starter. The farm system takes a hit, but you're buying wins now.
What Happens Next
The tender offer is expected to launch shortly, with the full deal closing between April and June 2026. Once complete, Day One becomes a wholly owned Servier subsidiary, and DAWN shares get delisted.
Meanwhile, Ipsen (which holds rights to tovorafenib outside the U.S.) is pushing toward European approval, and a regulatory decision is expected sometime this year. A positive outcome there would extend Ojemda's commercial reach well beyond American borders.
The real test comes with FIREFLY-2. If that Phase 3 trial delivers positive results in the front-line setting, Servier won't just own a second-line treatment for a rare pediatric cancer. It'll own the standard of care, from first diagnosis to relapse. In a market where competitors are scarce and patient need is urgent, that's worth a whole lot more than $2.5 billion.
Deals & M&A5 min read
IQVIA Just Bought the Part of Charles River That Sees the Future
IQVIA is paying $145 million for Charles River's European discovery labs and AI platform, giving it something it's never had: real drug discovery muscle from day one. The deal bets big on non-animal testing methods and AI-driven chemistry at a moment when regulators are rewriting the rules of preclinical research.
